文献速递甲状腺疾病

左甲状腺素治疗与甲状腺过氧化物酶抗体和抗抑郁药使用的关联:一项丹麦人群纵向研究

Association of Levothyroxine Treatment and Thyroid Peroxidase Antibodies with Antidepressant Use: A Danish Population-Based Longitudinal Study.
PubMed 文献 · Thyroid · 2022-11-30

基于丹麦GESUS队列12,894人,基线时2,353人(18%)有过去或当前抗抑郁药使用,10,541人进入随访,中位随访7.8年期间783人(占10,541人的7.4%)新发抗抑郁药使用。TPOAb阳性与过去或当前(OR 0.90 [CI 0.78-1.03],p=0.13)及新发(HR 1.02 [CI 0.83-1.25],p=0.88)抗抑郁药使用均无关;LT4治疗与过去或当前(OR 1.33 [CI 1.10-1.62],p=0.004)及新发(HR 1.38 [CI 1.03-1.85],p=0.03)抗抑郁药使用增加相关。TPOAb阳性与LT4治疗之间无交互作用(logistic p=0.87;Cox p=0.82)。

要点

  • TPOAb阳性与过去或当前及新发抗抑郁药使用均无关联。
  • LT4治疗与过去或当前及新发抗抑郁药使用增加相关。
  • TPOAb阳性与LT4治疗对抗抑郁药使用无交互作用。

核心结论

  • LT4治疗而非TPOAb阳性与至少一次抗抑郁药处方的现患或新发使用增加相关。
  • 研究结果不支持甲状腺自身免疫是接受LT4治疗患者抗抑郁药使用的重要因素。

研究设计与样本

  • 基于丹麦一般郊区人群研究(GESUS)2010-2013年基线生化和问卷数据,链接国家健康登记处的个体纵向数据。
  • 纳入12,894人,其中2,353人(18%)基线有过去或当前抗抑郁药使用,10,541人进入基线后新发抗抑郁药使用风险集。
  • 采用logistic回归评估基线前抗抑郁药使用启动,Cox回归评估基线后新发使用,所有暴露和协变量固定在基线检查日期。
  • 甲状腺自身免疫定义为血清TPOAbs >60 U/mL,调整性别、年龄、教育、收入、Charlson合并症指数、吸烟和酒精。
  • 敏感性分析针对缺失变量、排除锂剂使用、排除甲状腺手术以及LT4治疗和抗抑郁药使用需至少两次处方的保守定义。

主要发现

  • 中位随访7.8年,10,541人中有783人(7.4%)新发抗抑郁药使用。
  • TPOAb阳性与过去或当前抗抑郁药使用无关(OR 0.90 [CI 0.78-1.03],p=0.13)。
  • TPOAb阳性与新发抗抑郁药使用无关(HR 1.02 [CI 0.83-1.25],p=0.88)。
  • LT4治疗与过去或当前抗抑郁药使用增加相关(OR 1.33 [CI 1.10-1.62],p=0.004)。
  • LT4治疗与新发抗抑郁药使用增加相关(HR 1.38 [CI 1.03-1.85],p=0.03)。

关键数值与推荐

  • 甲状腺自身免疫定义为血清TPOAbs >60 U/mL。
  • 敏感性分析稳健,但新发使用至少两次抗抑郁药处方未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 新发使用至少两次抗抑郁药处方的敏感性分析未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Subjects receiving levothyroxine (LT4) treatment have increased prevalence of depression, anxiety, and antidepressant use, but whether the underlying mechanism relates to thyroid autoimmunity is still unclarified. Methods: This is a population-based longitudinal study. Baseline biochemical and questionnaire data from the Danish General Suburban Population Study (GESUS) in 2010-2013 were linked with individual-level longitudinal data in national health registries. The aim was to investigate the associations between thyroid peroxidase antibodies (TPOAbs) and LT4 treatment, separately and through interaction, and at least one redeemed prescription for antidepressants. Logistic and Cox regression were used to evaluate initiation of antidepressant use before and after the baseline examination in GESUS, respectively. All exposures and covariates were fixed at the date of baseline examination. Thyroid autoimmunity was defined as serum TPOAbs >60 U/mL. Adjustments included sex, age, education, income, Charlson comorbidity index, smoking, and alcohol. Sensitivity analyses were performed for missing variables, exclusion of lithium use, exclusion of thyroid surgery, and conservative definitions for LT4 treatment and antidepressant use requiring at least two prescriptions. Results: We included 12,894 individuals, of whom 2353 (18%) had "past or current" antidepressant use at baseline, leaving 10,541 individuals at risk for incident antidepressant use after baseline. The median follow-up was 7.8 years during which 783 individuals (7.4% of 10,541 individuals) had incident antidepressant use. TPOAb positivity was not associated with "past or current" (odds ratio [OR] 0.90 [confidence interval, CI 0.78-1.03], p = 0.13) nor incident antidepressant use (hazard ratio [HR] 1.02 [CI 0.83-1.25], p = 0.88). LT4 treatment was associated with increased "past or current" antidepressant use (OR 1.33 [CI 1.10-1.62], p = 0.004) and increased incident antidepressant use (HR 1.38 [CI 1.03-1.85], p = 0.03). There were no interactions between the effects of TPOAb positivity and LT4 treatment on the use of antidepressants in logistic (p = 0.87) or Cox regression models (p = 0.82). Sensitivity analyses were robust, except that incident use of at least two redeemed antidepressant prescriptions was not statistically significant. Conclusions: LT4 treatment, but not TPOAb positivity, was associated with increased prevalent or incident antidepressant use with at least one prescription. Our findings do not support that thyroid autoimmunity is an important factor for antidepressant use in patients receiving LT4 treatment.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jensen CZ, la Cour JL, Watt T, et al. Association of Levothyroxine Treatment and Thyroid Peroxidase Antibodies with Antidepressant Use: A Danish Population-Based Longitudinal Study. Thyroid. 2022. PMID: 36222609. doi:10.1089/thy.2022.0335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。